Detalhe da pesquisa
1.
Empagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
; 388(2): 117-127, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36331190
2.
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Circulation
; 2024 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38583093
3.
SGLT2 Inhibitors: The Sweet Success for Kidneys.
Annu Rev Med
; 74: 369-384, 2023 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706745
4.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Lancet
; 403(10424): 379-390, 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38109916
5.
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
J Am Soc Nephrol
; 35(2): 202-215, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38082486
6.
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.
Diabetologia
; 67(1): 3-18, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37801140
7.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
N Engl J Med
; 384(2): 129-139, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200891
8.
Virtual Pharmacy: An Integrated Collaborative Redesign Targeting Medication-Related Problems in Patients with Chronic Kidney Disease.
Am J Nephrol
; 55(2): 206-213, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37939689
9.
Proximal versus distal diuretics in congestive heart failure.
Nephrol Dial Transplant
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38425090
10.
An update review of post-transplant diabetes mellitus: Concept, risk factors, clinical implications and management.
Diabetes Obes Metab
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38558257
11.
Inter-relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management.
Diabetes Obes Metab
; 26(5): 1567-1581, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328853
12.
Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition.
Circulation
; 146(6): 450-462, 2022 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35862082
13.
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Circulation
; 145(19): 1460-1470, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35394821
14.
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
Kidney Int
; 103(4): 772-781, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738891
15.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
N Engl J Med
; 383(15): 1425-1435, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966714
16.
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
N Engl J Med
; 382(26): 2493-2503, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32579810
17.
Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.
Am J Kidney Dis
; 82(6): 737-742, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37517546
18.
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
Diabetes Obes Metab
; 25(6): 1646-1657, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36782093
19.
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
Diabetes Obes Metab
; 25(8): 2218-2226, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37232058
20.
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
Diabetes Obes Metab
; 25(3): 758-766, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394384